ArticleScientific reports2025
Comparative assessment of the Sikun 2000 sequencing platform for whole genome sequencing.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
DNA sequencing technology has significantly advanced over the past five decades, particularly with the introduction of next-generation sequencing (NGS) platforms like Illumina's NovaSeq. In October 2023, Sikun introduced the Sikun 2000, a desktop NGS platform designed for rapid, cost-effective sequencing with up to 200 Gb of data per run. This study is the first to evaluate the performance of the Sikun 2000 in whole genome sequencing (WGS) and compares it with the Illumina NovaSeq 6000 and NovaSeq X platforms using five well-characterized human Genomes in a Bottle dataset. Results show that the Sikun 2000 performs competitively in variant detection, particularly excelling in single nucleotide variant accuracy. It also demonstrated a higher sequencing depth and lower proportion of low-quality reads than the NovaSeq platforms. However, its performance in insertion-deletion (Indel) detection was slightly lower than that of NovaSeq platforms. Overall, the Sikun 2000 is a qualified sequencing platform for WGS, and further evaluation in clinical and research applications is required as data continues to accumulate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.